brexpiprazole

DRUG INTERACTION

Contraindicated  

Serious Use Alternative  

Monitor Closely  

Minor  

Frequency defined:  

>10% 

Akathisia 

1-10% 

MDD 

Dizziness 

Fatigue 

Headache 

Anxiety 

Nasopharyngitis 

Increased appetite 

Somnolence 

Restlessness 

Schizophrenia 

Dyspepsia 

Sedation 

Akathisia 

Increased weight 

Diarrhea 

Frequently not defined 

Myalgia 

Blurred vision 

Nausea 

Insomnia 

Salivary hypersecretion 

Hyperhidrosis 

Post-marketing reports 

Malignant syndrome 

Pregnancy consideration: Insufficient data available 

Lactation: Excretion of the drug in human breast milk is unknown  

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh the risks over benefits. These category drugs should be prohibited for pregnant women. 
• Category N: No data is available for the drug under this category. 

Patient information leaflet 

Generic Name: brexpiprazole 

Pronounced: brek-SPIP-rə-zohl 

Why do we use brexpiprazole? 

It is used to treat schizophrenia symptoms such as disturbed thinking, intense emotions in adults and children